Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00143481|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : April 10, 2013
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence||Drug: Tolterodine ER 4mg QD||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder|
|Study Start Date :||March 2005|
|Actual Primary Completion Date :||June 2006|
- Change in number of episodes of urgency urinary incontinence (UUI) at week 12 compared with baseline.
- Change in total number of urgency urinary incontinence (UUI) episodes at weeks 4 and 24 compared with baseline
- Change in total number of daytime urgency urinary incontinence (UUI) episodes at week 4, week 12, and week 24 compared with baseline
- Change in total number of pads used per 24 hours at weeks 4, 12, and 24 compared with baseline
- Reasons for treatment withdrawal
- Adverse Events during the 24 week treatment period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143481
|Study Director:||Pfizer CT.gov Call Center||Pfizer|